The FT Global Pharmaceutical and Biotechnology Conference, now in its 34th successful year brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in an industry in flux.
Transformational shifts in healthcare markets herald challenges as well as opportunities ahead for the global life science industry. Considerations around value and outcomes of drug and other medical interventions are becoming a part of the fabric of the industry as health technology assessment and integrated care models gain traction in a growing number of markets. Some 15 years after the sequencing of the human genome, renewed efforts are under way to ensure that the vision of personalised healthcare becomes a reality, whilst the pace of digital health innovations continues, offering both new opportunities to engage with patients and also new competitors in the shape of data savvy companies increasingly encroaching in pharma’s traditional space. The new reality for life sciences companies is a blurring of traditional industry boundaries, and a need to collaborate at an unprecedented rate.